RAC 0.97% $1.54 race oncology ltd

Industry news, page-583

  1. 2,712 Posts.
    lightbulb Created with Sketch. 2824
    the first point you made is important. A lot of take over stats show a premium to SP. but as compared to ATH they can be heavily discounted eg VLA and RAP down from $0.38c in October 2019.

    I think it is difficult for BOD to be objective, if they see a sale as the only way for them to exit. If in the millions they possibly don’t mind taking a hair cut but that doesn’t help the little guy who is in the red!

    Having competition is key, if Pzifer is a last ditch effort then rejecting it could risk the one and only deal. Not a good position to be in. Pzifer holds all the cards in this instance a market is crap so they are trying to scoop a bargain.

    That’s why being under the radar ain’t such a bad thing atm. There needs to clearly be an on the radar strategy / campaign at some point to rollout to market!

    not in RAP but will be interesting to see the outcome.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.